Fig. 4

Neuroprotective effects of WLR in the peripheral nerves of OXIPN animals. a Induction of neuropathy by oxaliplatin (L-OHP) and drug administration were done as described in Fig. 2. Four weeks after administration of WLR (250 mg/kg, 6 times a week) or amifostine (Ami, 100 mg/kg, once a week), the footpads of the experimental animals were procured and subjected to immunohistochemical analyses. IENFs in the footpads were detected with the PGP9.5 specific antibody. IENFs that were immunostained with the pan-axonal marker PGP9.5 were vertically arrayed within the epidermis (arrows, X400). b Innervation of the IENFs through the mouse skins was quantified by scoring the IENFs within sections of the footpads and expressed as densities of IENFs (fibers/mm). *p < 0.05 vs saline control mice (Ctrl); ^# p < 0.05 vs. oxaliplatin (L-OHP) and vehicle (Veh)-treated mice. The data represent the combined results of n = 8 experiments